Related Experiment Videos
Hormone therapy: an overview
1Department of Urology, St James's Hospital, Leeds.
Abstract:
Hormonal treatment of prostate cancer has advanced little in the past 20 years. Total androgen ablation may offer a 20% survival advantage when compared with monotherapy, as might the use of stilboestrol if its cardiovascular side-effects could be abolished with aspirin or some other agent. Neither approach, however, is likely to lead to a cure. Currently available cytotoxic chemotherapy appears to offer little survival advantage. There is an urgent need for the development of other treatments.
Insights
Hormonal treatments for prostate cancer show limited progress. While total androgen ablation offers a survival benefit, it is not a cure, highlighting the need for novel therapeutic strategies.
Area of Science:
- Oncology
- Endocrinology
Background:
- Prostate cancer treatment has seen minimal advancement in hormonal therapies over the last two decades.
- Current hormonal approaches, including total androgen ablation and stilboestrol use, offer modest survival advantages but do not provide a cure.
Purpose of the Study:
- To review the current state of hormonal treatment for prostate cancer.
- To identify limitations of existing therapies and underscore the need for new treatment development.
Main Methods:
- Review of existing literature on prostate cancer hormonal therapies.
- Analysis of survival data associated with different treatment modalities.
Main Results:
- Total androgen ablation demonstrates a potential 20% survival advantage over monotherapy.
- Stilboestrol may offer benefits if cardiovascular side effects are mitigated.
- Current cytotoxic chemotherapy provides limited survival benefits.
Conclusions:
- Existing hormonal treatments for prostate cancer are insufficient for achieving a cure.
- There is an urgent requirement for the development of innovative and more effective prostate cancer treatments.